Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Kjekshus

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Journal of Cardiac Failure|August 28, 2010
Effects of ACE2 inhibition in the post-myocardial infarction heartMyung-A Kim, Dongheon Yang, Keisuke Kida, et al.
Circulation|November 18, 2009
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysisJohn J V McMurray, John Kjekshus, Lars Gullestad, et al.
European Heart Journal|March 31, 2009
Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failureArne Yndestad, Linn Landrø, Thor Ueland, et al.
Journal of the American College of Cardiology|November 7, 2009
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)John G F Cleland, John J V McMurray, John Kjekshus, et al.
European Heart Journal|April 20, 2012
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Lars Gullestad, Thor Ueland, John Kjekshus, et al.
European Journal of Heart Failure|February 3, 2015
Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA)Vincent G Haver, Irene Mateo Leach, John Kjekshus, et al.
Atherosclerosis. Supplements|November 9, 2004
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998Terje R Pedersen, Anders G Olsson, Ole Faergeman, et al.
JACC. Heart Failure|April 12, 2014
Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)Ana Cristina Perez-Moreno, Pardeep S Jhund, Michael R Macdonald, et al.
Circulation|March 27, 2015
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) TrialsAzmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L Fulton, et al.
Circulation|December 2, 2015
Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials."Azmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L Fulton, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Journal of Cardiac Failure|August 28, 2010
Effects of ACE2 inhibition in the post-myocardial infarction heartMyung-A Kim, Dongheon Yang, Keisuke Kida, et al.
Circulation|November 18, 2009
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysisJohn J V McMurray, John Kjekshus, Lars Gullestad, et al.
European Heart Journal|March 31, 2009
Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failureArne Yndestad, Linn Landrø, Thor Ueland, et al.
Journal of the American College of Cardiology|November 7, 2009
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)John G F Cleland, John J V McMurray, John Kjekshus, et al.
European Heart Journal|April 20, 2012
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Lars Gullestad, Thor Ueland, John Kjekshus, et al.
European Journal of Heart Failure|February 3, 2015
Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA)Vincent G Haver, Irene Mateo Leach, John Kjekshus, et al.
Atherosclerosis. Supplements|November 9, 2004
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998Terje R Pedersen, Anders G Olsson, Ole Faergeman, et al.
JACC. Heart Failure|April 12, 2014
Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)Ana Cristina Perez-Moreno, Pardeep S Jhund, Michael R Macdonald, et al.
Circulation|March 27, 2015
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) TrialsAzmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L Fulton, et al.
Circulation|December 2, 2015
Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials."Azmil H Abdul-Rahim, Ana-Cristina Perez, Rachael L Fulton, et al.
Pageof 12